Trial Profile
A phase 2 trial of VTP-500
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Therapeutic Use
- 26 Dec 2023 New trial record
- 21 Dec 2023 According to a Barinthus Biotherapeutics media release, the company plans a project with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford aiming to fast-track the development of a vaccine candidate known as VTP-500. If the vaccine is successful in Phase II trials, CEPI will support production of an investigational ready reserve of 100,000 doses which can be rapidly deployed in a clinical trial setting in response to an outbreak of MERS.